This trial studies how well Cerenkov luminescence imaging in diagnosing participants with cancer who are undergoing fludeoxyglucose F-18 positron emission tomography, iodine 131 therapy, radium Ra 223 dichloride (223Ra therapy [Xofigo]), gallium Ga 68-high affinity (HA)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-acetic acid (DOTA)- iodo-tyrosine-3-octreotate (TATE) (68Ga-DOTATATE), lutetium Lu 177 DOTATATE (177Lu-DOTATATE), or fluorine F 18 [18F]-PARP inihibitor (PARPi). Cerenkov luminescence imaging may be able to capture tumor sizes and may be used as a guide for surgical resections.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03484884.
PRIMARY OBJECTIVE:
I. To explore the overall feasibility of clinical Cerenkov imaging on patients with any tumors with nodal metastases (existing or suspected) scheduled for routine clinical fludeoxyglucose F-18 (FDG) positron emission tomography (PET), iodine 131 (131I) therapy, 223Ra therapy (Xofigo), 68Ga-DOTATATE, 177Lu-DOTATATE, or 18F-PARPi.
SECONDARY OBJECTIVES:
I. Correlate Cerenkov imaging signal with uptake of the radiotracer and evaluate the spectral distribution of the signal.
II. Correlate the peak wavelength (spectral characteristics of the Cerenkov light exiting the body) with the depth of the signal in the body.
III. Examine if we can obtain signal from deeper lying regions in the body (below the subcutaneous and axillary fat) or from within the body (oral cavity in this case).
IV. Compare the follow-up scan of Cerenkov imaging to scintigraphy.
OUTLINE:
Participants undergo Cerenkov luminescence imaging after their standard of care FDG PET, 131I therapy, 223Ra therapy, 68Ga-DOTATATE, 177Lu-DOTATATE, or 18F-PARPi.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorJan Grimm
